Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
6-month BPaL regimen for fluoroquinolone-resistant multidrug-resistant tuberculosis
KCT0007234Phase 4Not yet recruiting
- Sponsor
- Korea Disease Control and Prevention Agency
- Start
- Jun 2022
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bedaquiline, pretomanid and linezolid in Tuberculosis (TB), sponsored by Korea Disease Control and Prevention Agency. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
bedaquilinepretomanidlinezolid
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on KCT0007234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0007234.